Platelet‐rich plasma treatment for melasma: A pilot study

2019 ◽  
Vol 19 (6) ◽  
pp. 1321-1327 ◽  
Author(s):  
Punyaphat Sirithanabadeekul ◽  
Arada Dannarongchai ◽  
Atchima Suwanchinda
2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Markus Loibl ◽  
Siegmund Lang ◽  
Lena-Marie Dendl ◽  
Michael Nerlich ◽  
Peter Angele ◽  
...  

A positive effect of intra-articular platelet-rich plasma (PRP) injection has been discussed for osteoarthritic joint conditions in the last years. The purpose of this study was to evaluate PRP injection into the trapeziometacarpal (TMC) joint. We report about ten patients with TMC joint osteoarthritis (OA) that were treated with 2 intra-articular PRP injections 4 weeks apart. PRP was produced using the Double Syringe System (Arthrex Inc., Naples, Florida, USA). A total volume of1.47±0.25 mL PRP was injected at the first injection and1.5±0.41 mL at the second injection, depending on the volume capacity of the joint. Patients were evaluated using VAS, strength measures, and the Mayo Wrist score and DASH score after 3 and 6 months. VAS significantly decreased from6.2±1.6to5.4±2.2at six-month follow-up (P<0.05). The DASH score was unaffected; however, the Mayo Wrist score significantly improved from46.5±18.6to67.5±19.0at six-month follow-up (P=0.05). Grip was unaffected, whereas pinch declined from6.02±2.99to3.96±1.77at six-month follow-up (P<0.05). We did not observe adverse events after the injection of PRP, except one occurrence of a palmar wrist ganglion, which resolved without treatment. PRP injection for symptomatic TMC OA is a reasonable therapeutic option in early stages TMC OA and can be performed with little to no morbidity.


Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 627-P
Author(s):  
WUQUAN DENG ◽  
MIN HE ◽  
BING CHEN ◽  
YU MA ◽  
DAVID ARMSTRONG ◽  
...  

2002 ◽  
Vol 60 (10) ◽  
pp. 1176-1181 ◽  
Author(s):  
Tara L. Aghaloo ◽  
Peter K. Moy ◽  
Earl G. Freymiller

2018 ◽  
Vol 8 (1) ◽  
pp. 1 ◽  
Author(s):  
Konstantinos Sfakianoudis ◽  
Mara Simopoulou ◽  
Nikolaos Nitsos ◽  
Anna Rapani ◽  
Athanasios Pappas ◽  
...  

This report presents the case of a woman aged 40 who has experienced premature menopause from the age of 35. Having rejected oocyte donation, she opted for intraovarian injection of autologous platelet-rich plasma with the aim to rejuvenate the ovarian tissue and enable the employment of her own gametes through in-vitro fertilization. Six weeks following the autologous platelet-rich plasma treatment, a significant reduction in the patient’s follicle-stimulating hormone (FSH) levels were noted. A natural in-vitro fertilization cycle led to a biochemical pregnancy, resulting in a spontaneous abortion at the 5th week of pregnancy. This is the first report of a successful autologous platelet-rich plasma application leading to pregnancy in menopause. This report uniquely contributes to the medical knowledge and challenges current practice in the context of infertility. The efficiency and safety of this treatment with regard to the reproductive system merits further investigation.


Sign in / Sign up

Export Citation Format

Share Document